Holen Sie sich die Stockscreener-App
0.3474
5.37%
0.0177
Handel nachbörslich:
.34
-0.0074
-2.13%
Schlusskurs vom Vortag:
$0.3297
Offen:
$0.3452
24-Stunden-Volumen:
6.91M
Relative Volume:
0.46
Marktkapitalisierung:
$81.53M
Einnahmen:
$48.47M
Nettoeinkommen (Verlust:
$-170.37M
KGV:
-0.4633
EPS:
-0.7499
Netto-Cashflow:
$-171.35M
1W Leistung:
-4.82%
1M Leistung:
-30.62%
6M Leistung:
-85.64%
1J Leistung:
-55.91%
1-Tages-Spanne:
$0.3222
$0.3494
1-Wochen-Bereich:
$0.32
$0.3814
52-Wochen-Spanne:
$0.32
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3474 | 77.38M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
GOSS Investor Alert: Gossamer Bio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects - marketscreener.com
Cantor Fitzgerald downgrades Gossamer Bio (GOSS) to neutral - MSN
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral - Yahoo Finance
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit — The Gross Law Firm - Morningstar
Holzer & Holzer, LLC Reminds Investors of June 1, 2026 Lead - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) - The National Law Review
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Stop Loss: Is Gossamer Bio Inc part of any ETFMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - Sahm
Gossamer Bio Lawsuit: Investors Allege Misleading Statements Ahead of Failed PAH Trial - TipRanks
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - lincolnjournal.com
User - The Chronicle-Journal
Investors Seek Lead in Gossamer Bio Securities Fraud Lawsuit - nationaltoday.com
GOSS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Gossamer Bio, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – GOSS - ChartMill
GOSS Investors Invited to Lead Securities Fraud Lawsuit Against Gossamer Bio - nationaltoday.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming DeadlinesGOSS - ChartMill
GOSS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Gossamer Bio, Inc. - ChartMill
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - lincolnjournal.com
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - stocktitan.net
Gossamer Bio, Inc. (4GB.MU) stock price, news, quote and history - Yahoo Finance Australia
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit - The AI Journal
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Gossamer Bio, Inc. (GOSS) Investors – ... - Caledonian Record
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Gossamer Bio, Inc. (GOSS) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - WBOC TV
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP - PR Newswire
Trading Action: Is Gossamer Bio Inc stock a smart retirement pick2026 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
683 Capital Management, LLC Reduces Stake in Gossamer Bio Inc - GuruFocus
Gossamer Bio (GOSS) price target decreased by 53.60% to 4.44 - MSN
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback - insidermonkey.com
Gossamer Bio Receives 'Hold' Rating from Analysts - National Today
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Vanguard reports zero beneficial holdings in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Cantor Fitzgerald downgrades Gossamer Bio (GOSS) - MSN
GOSS (Gossamer Bio) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - PR Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Legal Scrutiny Intensifies for Gossamer Bio Following Clinical Trial Setback () - aktiencheck.de
Options Flow: Is Gossamer Bio Inc a stock for growth or value investorsPortfolio Performance Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
GOSS Technical Analysis | Trend, Signals & Chart Patterns | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio (GOSS) continues downtrend despite impressive revenue - MSN
Setup Watch: Should I set a stop loss on Gossamer Bio IncTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.51%
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):